Spine BioPharma, Inc. Announces Completion of Enrollment for Phase 3 Clinical Trial of SB-01 to Address Chronic Low Back Pain
OrthoSpineNews
SEPTEMBER 24, 2024
NEW YORK, September 24, 2024 –(BUSINESS WIRE)– Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced the completion of enrollment of its U.S. Phase 3 clinical trial of SB-01 For Injection (SB-01).
Let's personalize your content